Recent update on the protective potentials of resveratrol against cisplatin-induced ototoxicity : a systematic review
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: Although cancer treatment with cisplatin is effective, dose-dependent adverse effects such as ototoxicity occurs often, which limits its clinical use. The use of resveratrol may alleviate the cisplatin-induced ototoxic effects. This study is aimed to review the potential otoprotective effects of resveratrol against cisplatin-induced ototoxicity.
METHOD: According to the PRISMA guideline, a systematic search was accomplished to identify all relevant scientific papers on "the role of resveratrol against cisplatin-induced ototoxicity" in different electronic databases up to May 2021. Fifty-five articles were screened based on a pre-defined set of inclusion and exclusion criteria. Eight eligible studies were finally included in the current systematic review. The in-vitro findings revealed that cisplatin administration significantly decreased the HEI-OC1 cell viability compared to the untreated cells; however, resveratrol co-treatment (in a dose-dependent manner) could protect HEI-OC1 cells against cisplatin-induced decrease in cell viability.
RESULTS: Furthermore, the in-vivo finding showed a decreased value of DPOAE, and increased values of ABR threshold, ABR-I, ABR-IV, and ABR I-IV interval in cisplatin-treated animals; in contrast, resveratrol co-administration demonstrated an opposite pattern on these parameters.
CONCLUSION: Thus, it can be mentioned that resveratrol co-treatment alleviates cisplatin-induced ototoxicity. Mechanically, resveratrol exerts its otoprotective effects through various mechanisms such as anti-oxidant, anti-apoptosis, and anti-inflammatory.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Current medicinal chemistry - (2023) vom: 24. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alsaikhan, Fahad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-in?ammatory |
|---|
| Anmerkungen: |
Date Revised 26.07.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0929867331666230724124013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359920152 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359920152 | ||
| 003 | DE-627 | ||
| 005 | 20231226081913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0929867331666230724124013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359920152 | ||
| 035 | |a (NLM)37491852 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alsaikhan, Fahad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent update on the protective potentials of resveratrol against cisplatin-induced ototoxicity |b a systematic review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a INTRODUCTION: Although cancer treatment with cisplatin is effective, dose-dependent adverse effects such as ototoxicity occurs often, which limits its clinical use. The use of resveratrol may alleviate the cisplatin-induced ototoxic effects. This study is aimed to review the potential otoprotective effects of resveratrol against cisplatin-induced ototoxicity | ||
| 520 | |a METHOD: According to the PRISMA guideline, a systematic search was accomplished to identify all relevant scientific papers on "the role of resveratrol against cisplatin-induced ototoxicity" in different electronic databases up to May 2021. Fifty-five articles were screened based on a pre-defined set of inclusion and exclusion criteria. Eight eligible studies were finally included in the current systematic review. The in-vitro findings revealed that cisplatin administration significantly decreased the HEI-OC1 cell viability compared to the untreated cells; however, resveratrol co-treatment (in a dose-dependent manner) could protect HEI-OC1 cells against cisplatin-induced decrease in cell viability | ||
| 520 | |a RESULTS: Furthermore, the in-vivo finding showed a decreased value of DPOAE, and increased values of ABR threshold, ABR-I, ABR-IV, and ABR I-IV interval in cisplatin-treated animals; in contrast, resveratrol co-administration demonstrated an opposite pattern on these parameters | ||
| 520 | |a CONCLUSION: Thus, it can be mentioned that resveratrol co-treatment alleviates cisplatin-induced ototoxicity. Mechanically, resveratrol exerts its otoprotective effects through various mechanisms such as anti-oxidant, anti-apoptosis, and anti-inflammatory | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-in?ammatory | |
| 650 | 4 | |a Anti-oxidant | |
| 650 | 4 | |a Cisplatin | |
| 650 | 4 | |a Neoplasms | |
| 650 | 4 | |a Ototoxicity | |
| 650 | 4 | |a Resveratrol | |
| 700 | 1 | |a Jasim, Saade Abdalkareem |e verfasserin |4 aut | |
| 700 | 1 | |a Margiana, Ria |e verfasserin |4 aut | |
| 700 | 1 | |a Opulencia, Maria Jade Catalan |e verfasserin |4 aut | |
| 700 | 1 | |a Yasin, Ghulam |e verfasserin |4 aut | |
| 700 | 1 | |a Hammid, Ali Thaeer |e verfasserin |4 aut | |
| 700 | 1 | |a Nasretdinova, Makhzuna Tahsinovna |e verfasserin |4 aut | |
| 700 | 1 | |a Mahdi, Ahmed B |e verfasserin |4 aut | |
| 700 | 1 | |a Farhood, Bagher |e verfasserin |4 aut | |
| 700 | 1 | |a Abedi-Firouzjah, Razzagh |e verfasserin |4 aut | |
| 700 | 1 | |a Jamialahmadi, Tannaz |e verfasserin |4 aut | |
| 700 | 1 | |a Sahebkar, Amirhosein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d 1997 |g (2023) vom: 24. Juli |w (DE-627)NLM093833857 |x 1875-533X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:24 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0929867331666230724124013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 24 |c 07 | ||